Cintia Piccina is Chief Commercial Officer at Adaptimmune Therapeutics PLC (ADAP). They have made 5 open-market trades across 2 companies since 2022, most recently 2026-09-02.
CIK 0001907199
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ALVR | 147,000 | $1.4M |
| AUTL | 13,287 | $21K |
| ADAP | 18,421 | $1K |
| Total | $1.5M |
Shares reported on the most recent Form 4, priced at the 2026-09-03 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AUTL | SELL | 2026-09-02 | 2026-09-03 | $2.34 | $16K | -18.7% | -20.5% | — |
| ADAP | SELL | 2025-01-15 | 2025-01-15 | $0.57 | $7K | -0.5% | -2.5% | -57.9% |
| ADAP | SELL | 2024-06-18 | 2024-06-18 | $0.93 | $23K | +20.7% | +35.6% | +20.7% |
| ADAP | SELL | 2023-01-31 | 2023-01-31 | $1.87 | $22K | -13.2% | -13.7% | -24.7% |
| ADAP | SELL | 2022-08-01 | 2022-08-01 | $1.77 | $37K | +31.6% | +15.8% | -17.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.